Generex Biotechnology Corp., headquartered in Toronto, Canada, is a clinical-stage biopharmaceutical company focused on developing and commercializing novel immunopharmacological products and drug-delivery platforms. Since its founding in the mid-1990s, the company has pursued innovative approaches to enhance the efficacy and patient experience of therapeutics, with an emphasis on non-invasive delivery methods and immuno-oncology applications.
The company’s core pipeline includes proprietary platforms such as an oral delivery system for insulin and other peptide-based drugs, as well as immunotherapeutic candidates targeting hematological and viral diseases. Among its lead programs are a novel agent for acute myeloid leukemia (AML) and an innovative treatment for chronic hepatitis B. Through its delivery technologies, Generex aims to improve bioavailability, reduce treatment burdens and expand the range of diseases addressable without reliance on conventional injection methods.
Generex maintains operations and strategic partnerships across North America and Asia, leveraging collaborations with academic institutions and contract research organizations to advance its clinical and preclinical studies. The company’s earlier vaccine development work, which included partnerships to produce pandemic influenza vaccines, underscores its commitment to rapid-response capabilities and global health initiatives. Its international reach provides access to diverse patient populations and supports broad regulatory engagement.
Under the guidance of a leadership team with decades of experience in biotechnology and pharmaceutical development, Generex continues to refine its technology platforms and advance its pipeline toward regulatory milestones. The executive management and board of directors bring expertise in clinical development, regulatory affairs and commercialization strategies, positioning the company to transition key assets from research to market.
AI Generated. May Contain Errors.
